BioVaxys details shareholder value with retention of Maxim to achieve US stock exchange listing

BioVaxys CEO James Passin joins Natalie Stoberman from the 35th International Papillomavirus Conference in Washington, D.C. to discuss its latest news of retaining New York City-based Maxim Group as its financial advisor and investment banker.

Passin says Maxim will handle strategic planning, assessment of potential strategic alliances and capital requirements, and advising the company with respect to the process of obtaining a listing on a US national stock exchange.

BioVaxys is a clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer.

Contact Details

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com